Open-to-Accrual Therapeutic Trials


Gynecologic Oncology

Trials are listed from Phase 1 to Phase 3, alphabetically.  Please click on the name of the Lead Clinical Research Coordinator (CRC) to request more information about each trial.

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

TESARO 4010-01-001      ClinicalTrials.gov   NCT0275284 Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors S. Ghamande Kelly Jenkins Advanced solid tumors I
C-550-01 ClinicalTrials.gov: NCT03495882 A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors Protocol Type: Treatment S. Ghamande Donna Wheatley Advanced Solid Tumors I/II
C-700-01  ClinicalTrials.gov:   NCT01772004 A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer S. Ghamande Renee Townsend  Cervical I/II
NRG-GY007 ClinicalTrials.gov  NCT02713386 A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Protocol Type: Treatment S. Ghamande Melissa James Ovarian, Fallopian Tube, or Peritoneal Cancer I/II
CL-PTL-126     ClinicalTrials.gov   NCT03073525 A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients with Advanced Gynecological Cancers S. Ghamande  Melissa James Cervical, Ovarian, and Uterine Cancer  II
GOG-3028/C-750-01 ClinicalTrials.gov  NCT03894215 A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS S. Ghamande Renee Townsend Cervical Cancer II
Inovio HPV-201 ClinicalTrials.gov  NCT03180684 A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA® 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous lntraepithelial Lesion (HSIL) of the Vulva Protocol D. Ferris Angela Goebel HPV Related HIgh Grade Squamous Intraepithelia Lesion (HSIL) II
LION C-145-04 ClinicalTrials.gov  NCT03108495 A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma S. Ghamande Renee Townsend Cervical Cancer II
NRG-GY006  ClinicalTrials.gov NCT02466971 
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer S. Ghamande  Kelly Adams Uterine Cervical or Vaginal Cancer II
NRG-GY017 ClinicalTrials.gov  NCT03738228 Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer S. Ghamande Joni Shortt Cervical Cancer II
SGNTV-002 ClinicalTrials.gov  NCT03657043 Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen S. Ghamande Donna Wheatley Ovarian Cancer II
NRG-GY009 ClinicalTrials.gov NCT02839707 A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer S. Ghamande Melissa James Ovarian Cancer II/III

GOG-0213 ClinicalTrials.gov NCT00565851

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) Protocol S. Ghamande Inquiries Ovarian, Primary Peritoneal, and Fallopian Tube Cancer III

GOG-3020/CO-338-087  ClinicalTrials.gov:  NCT03522246   

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) S. Ghamande Melissa James Ovarian Cancer III
GOG-3025/DUO-O ClinicalTrials.gov:  NCT03737643 A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients S. Ghamande Melissa James Ovarian Cancer III
MK7902-001 ClinicalTrials.gov:  NCT03884101 A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001) S. Ghamande Donna Wheatley Endometrial Cancer III
SOLO-3/ D0816C00010   ClinicalTrials.gov   NCT02282020 A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations S. Ghamande Melissa James Ovarian Cancer  III